TY - JOUR
T1 - History of comorbidities and survival of ovarian cancer patients, results from the ovarian cancer association consortium
AU - Minlikeeva, Albina N.
AU - Freudenheim, Jo L.
AU - Eng, Kevin H.
AU - Cannioto, Rikki A.
AU - Friel, Grace
AU - Szender, J. Brian
AU - Segal, Brahm
AU - Odunsi, Kunle
AU - Mayor, Paul
AU - Diergaarde, Brenda
AU - Zsiros, Emese
AU - Kelemen, Linda E.
AU - Kobel, Martin
AU - Steed, Helen
AU - Defazio, Anna
AU - Jordan, Susan J.
AU - Fasching, Peter A.
AU - Beckmann, Matthias W.
AU - Risch, Harvey A.
AU - Rossing, Mary Anne
AU - Doherty, Jennifer A.
AU - Chang-Claude, Jenny
AU - Goodman, Marc T.
AU - Dörk, Thilo
AU - Edwards, Robert
AU - Modugno, Francesmary
AU - Ness, Roberta B.
AU - Matsuo, Keitaro
AU - Mizuno, Mika
AU - Karlan, Beth Y.
AU - Goode, Ellen L.
AU - Kjaer, Susanne K.
AU - Høgdall, Estrid
AU - Schildkraut, Joellen M.
AU - Terry, Kathryn L.
AU - Cramer, Daniel W.
AU - Bandera, Elisa V.
AU - Paddock, Lisa E.
AU - Kiemeney, Lambertus A.
AU - Massuger, Leon F.A.G.
AU - Sutphen, Rebecca
AU - Anton-Culver, Hoda
AU - Ziogas, Argyrios
AU - Menon, Usha
AU - Gayther, Simon A.
AU - Ramus, Susan J.
AU - Gentry-Maharaj, Aleksandra
AU - Pearce, Celeste L.
AU - Wu, Anna H.
AU - Kupryjanczyk, Jolanta
AU - Jensen, Allan
AU - Webb, Penelope M.
AU - Moysich, Kirsten B.
N1 - Publisher Copyright:
© 2017 American Association for Cancer Research.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Background: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients. Methods: Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled HRs and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes. Results: None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histologic subtype, weight status, age at diagnosis, or stage of disease (local/regional vs. advanced). Conclusions: Histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival. Impact: These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis.
AB - Background: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients. Methods: Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled HRs and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes. Results: None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histologic subtype, weight status, age at diagnosis, or stage of disease (local/regional vs. advanced). Conclusions: Histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival. Impact: These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis.
UR - https://www.scopus.com/pages/publications/85028923106
U2 - 10.1158/1055-9965.EPI-17-0367
DO - 10.1158/1055-9965.EPI-17-0367
M3 - Article
C2 - 28864456
AN - SCOPUS:85028923106
SN - 1055-9965
VL - 26
SP - 1470
EP - 1473
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 9
ER -